NCT01615614View on ClinicalTrials.gov

A Study to Explore the Pharmacokinetics of Rilpivirine With Rifabutin in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Healthy
Interventions
DRUG

Rilpivirine

Type=exact number, unit=mg, number=25, 50, and will be determined after treatment A and B analysis form=tablet, route=oral. Once or twice daily with a total daily dose of rilpivirine between 25 and 75 mg will be administered for 11 days.

DRUG

Rifabutin

Type=exact number, unit=mg, number=150, form=capsule, route=oral. Two capsules daily will be administered for 17 days.

Trial Locations (1)

Unknown

Merksem

All Listed Sponsors
lead

Janssen R&D Ireland

INDUSTRY

NCT01615614 - A Study to Explore the Pharmacokinetics of Rilpivirine With Rifabutin in Healthy Participants | Biotech Hunter | Biotech Hunter